Our vision is to TRANSFORM LIFE-THREATENING DISEASES INTO TREATABLE CONDITIONS by designing truly INDIVIDUALIZED therapeutics that can specifically target each patient’s disease-causing agent at EVERY stage of the disease!
Aummune’s flexible, adaptable and evolving platform addresses the still unmet need for highly personalized, targeted, safe and agile therapies for widespread, life-threatening diseases that have immense social and economic impact:
cancer, antibiotic-resistant bacteria, and viruses.
Experienced bio-medical executive with a successful track record. Formerly CEO of Check-Cap, which he led from inception through to its NASDAQ IPO. Previously CEO at Healthwatch and Cappella (now Arravasc); cardiovascular BU Manager at Boston Scientific; executive positions with St. Jude Medical in Israel.
Dr. Ido Bachelet
Led groundbreaking research into medical nanorobotics, unconventional computing, programmable objects, and human-machine interfaces at MIT, Harvard and Bar-Ilan University, supported by US, EU, and Israeli grants. Founded US and Israeli companies in the fields of infectious diseases and computer vision.
Irit Carmi-Levy, PhD
Drug development expert and immunologist by training. Prior to joining to Aummune, served as a Project Director in BioLineRx, leading and overseeing all aspects of scientific, R&D, CMC, regulatory and clinical activities for several clinical and pre-clinical programs, including an immune-oncology project. Postdoctoral research at the Curie Institute and PhD in Biochemistry and Molecular Biology from Hebrew University .
Dr. Yair Schindel
Managing partner and co-founder of aMoon. A successful executive, investor, board or advisory board member in several healthcare startups. Founding CEO of the State of Israel’s National Digital Bureau and of the MAOZ Network, an NGO building collaboration between Israel’s most influential leaders.
Co-founder and partner at aMoon. Previously co-founded Check Point Software Technologies Ltd. (NASDAQ:CHKP), a global pioneer of cybersecurity and the largest company in Israel. Nacht is considered one of the founding fathers of Israel’s global cybersecurity industry.
Prof. Raanan Berger
Prof. Raanan Berger is director of the Institute of Oncology at the Sheba Medical Center. His MD and PhD degrees are from Tel Aviv University and he was a postdoctoral fellow at the Dana Farber Cancer Institute at Harvard Medical School. On 2006 he established the Oncology Clinical Research Center at Sheba, which is the largest center for all-phase oncology clinical trials in Israel.